During the European Hematology Association (EHA) 2024 Congress , Dr. Jabbour spoke with Blood Cancers Today on his top highlights in myelodysplastic syndromes (MDS) so far.
Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.